Anzeige
Meldung des Tages: ALLZEITHOCH: EchoIQ bei 1$ AUD – der größte Trigger steht unmittelbar bevor

Abivax News

Aktie
WKN:  A14UQC ISIN:  FR0012333284 US-Symbol:  AAVXF Branche:  Biotechnologie Land:  Frankreich
107,30 €
+1,00 €
+0,94%
15:18:46 Uhr
Depot/Watchlist
Marktkapitalisierung *
7,46 Mrd. €
Streubesitz
54,81%
KGV
-2,41
Index-Zuordnung
-

Abivax News

01.04.26 - EQS
EQS-News: Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies 01.04.2026 / 22:05 CET/CEST The ...
24.03.26 - 4investors
Abivax-Verlust steigt deutlich - Phase-3-Daten für Obefazimod rücken näher
23.03.26 - EQS
EQS-News: Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
EQS-News: ABIVAX / Key word(s): Annual Results Abivax Announces Full Year 2025 Financial Results and Provides Business Updates 23.03.2026 / 21:05 CET/CEST The issuer is ...
21.02.26 - EQS
EQS-News: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
EQS-News: ABIVAX / Key word(s): Study results Abivax Presents First Evidence of Anti-​Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in ...
07.01.26 - EQS
EQS-News: Abivax Provides 2026 Corporate Outlook
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax Provides 2026 Corporate Outlook 07.01.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this ...
21.12.25 wallstreetONLINE Redaktion
Europas absoluter Highflyer: Diese Aktie ist 2025 um 1.400 % explodiert – und es geht weiter
Studien, Zulassung, Übernahmegerüchte: Nach der Rekordrallye von Abivax stehen für die Aktie mehrere richtungsweisende Meilensteine an.Die Aktie des französischen Biotech-...
18.12.25 - EQS
EQS-News: Abivax to be Added to Nasdaq Biotechnology Index
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax to be Added to Nasdaq Biotechnology Index 18.12.2025 / 22:05 CET/CEST The issuer is solely responsible for the content of ...
17.12.25 - EQS
EQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
EQS-News: ABIVAX / Key word(s): Conference/Study results Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, ...
15.12.25 - EQS
EQS-News: Abivax Presents Third Quarter 2025 Financial Results
EQS-News: ABIVAX / Key word(s): Quarter Results Abivax Presents Third Quarter 2025 Financial Results 15.12.2025 / 22:05 CET/CEST The issuer is solely responsible for the ...
03.11.25 - EQS
EQS-News: Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Ulcerative Colitis
EQS-News: ABIVAX / Key word(s): Study results Abivax Announces Patient-​Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating ...
06.10.25 - EQS
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: ABIVAX / Key word(s): Conference/Study results Abivax Announces Late-​Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and ...
05.10.25 - EQS
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
EQS-News: ABIVAX / Key word(s): Conference/Study results Abivax Announces Late-​Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 05.10.2025 / ...
29.09.25 - EQS
EQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: ABIVAX / Key word(s): Conference Abivax Announces Acceptance of Additional Late-​Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 ...
23.09.25 - EQS
EQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
EQS-News: ABIVAX / Key word(s): Conference Abivax Announces Presentation of Late-​Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United ...
12.09.25 - EQS
EQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review 12.09.2025 / 17:45 CET/CEST The issuer ...
08.09.25 - EQS
EQS-News: Abivax Presents First Half 2025 Financial Results
EQS-News: ABIVAX / Key word(s): Half Year Results Abivax Presents First Half 2025 Financial Results 08.09.2025 / 22:00 CET/CEST The issuer is solely responsible for the content ...
08.09.25 wallstreetONLINE Redaktion
Earnings Preview: Jetzt schlägt für Adobe, GameStop und SAP-Rivale Oracle die Stunde der Wahrheit!
Diese in den kommenden Tagen (KW37) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
07.09.25 wallstreetONLINE Redaktion
Earnings Preview: Jetzt müssen sich Adobe, GameStop und SAP-Rivale Oracle ins Zeug legen!
Diese in den kommenden Tagen (KW37) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
01.09.25 wallstreetONLINE Redaktion
Von 500 Mio. auf 6 Mrd.: Biotech-Rakete legt über 900 Prozent zu – Anleger reiben sich die Augen
Mitten im schwachen Biotech-​Jahr liefert Abivax das Kurswunder: Aktie und Marktwert verfielfachen sich, Hedgefonds feiern einen ihrer größten Coups 2025.Der französische ...
28.07.25 - EQS
EQS-News: Abivax Announces Closing of $747.5 Million Public Offering
EQS-News: ABIVAX / Key word(s): Capital Increase Abivax Announces Closing of $747.5 Million Public Offering 28.07.2025 / 22:15 CET/CEST The issuer is solely responsible for the ...

Newssuche

Videos

newspaper
07.04.26 +0,66%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: VJ9H40 Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »